Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
07:40am, Sunday, 11'th Jan 2026
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
10:00am, Saturday, 10'th Jan 2026
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver m
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
09:52am, Saturday, 10'th Jan 2026
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive
Johnson & Johnson $JNJ Shares Sold by Cerity Partners LLC
03:40am, Saturday, 10'th Jan 2026
Cerity Partners LLC lowered its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 1.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Com
Market Today: Meta taps nuclear; GM books $6B EV charge
05:35pm, Friday, 09'th Jan 2026
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
J&J Finds Middle Ground in Washington
12:49pm, Friday, 09'th Jan 2026
Johnson and Johnson (JNJ) is making a very Washington style trade off. The company said it has reached an agreement with the Trump administration to lower drug pr
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
11:55am, Friday, 09'th Jan 2026
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio
11:45am, Friday, 09'th Jan 2026
AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.
Cramer's Mad Dash: Johnson & Johnson
09:59am, Friday, 09'th Jan 2026
CNBC's Jim Cramer delivers his daily Mad Dash.
First Look: GM's $7.1B EV Charge, Paramount's $30 WBD Bid
07:38am, Friday, 09'th Jan 2026
Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us
Breakfast News: TSM Defies Bubble Fears
07:30am, Friday, 09'th Jan 2026
TSM enjoys revenue surge, Nvidia adds CMO for brand recognition, jobs report due, and more
Johnson & Johnson Strikes Deal With White House to Lower Drug Prices
05:10am, Friday, 09'th Jan 2026
Trump administration secures deal with Johnson & Johnson to reduce price of some medicines
Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts
03:27am, Friday, 09'th Jan 2026
Johnson and Johnson struck a deal with the Trump administration to lower drug prices for U.S. consumers in exchange for exemptions from tariffs.
Almanack Investment Partners LLC. Has $2.42 Million Position in Johnson & Johnson $JNJ
03:04am, Friday, 09'th Jan 2026
Almanack Investment Partners LLC. grew its holdings in Johnson and Johnson (NYSE: JNJ) by 29.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The instituti
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
09:33pm, Thursday, 08'th Jan 2026
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
